SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

SAN

76.74

+2.12%↑

ARGX

687.2

+0.23%↑

SHL.DE

34.31

+1%↑

FRE

40.16

+1.24%↑

PHIA

22.99

+2.18%↑

Home・Akcijų sąrašas・Nanobiotix

N
Nanobiotix

Uždarymo kaina

36.8 -4.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

35.38

Max

38.48

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-13M -19M
Pardavimai	-24M 3M
Pelno marža	-618.236
Darbuotojai	100
EBITDA	-14M -13M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+55.93% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	592M 1.9B
Ankstesnė atidarymo kaina	41.17
Ankstesnė uždarymo kaina	36.8

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

2.975 / 3.015 Palaikymas ir pasipriešinimas

Nanobiotix Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-20 23:31; UTC

Karštos akcijos

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026-05-20 22:52; UTC

Pagrindinės rinkos jėgos

Osisko Shares Fall on Planned Convertible Notes Offering

2026-05-20 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-20 23:44; UTC

Uždarbis

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026-05-20 23:35; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026-05-20 23:30; UTC

Rinkos pokalbiai

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026-05-20 23:15; UTC

Rinkos pokalbiai

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026-05-20 23:14; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026-05-20 23:02; UTC

Rinkos pokalbiai

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 22:27; UTC

Rinkos pokalbiai

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026-05-20 22:14; UTC

Rinkos pokalbiai

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026-05-20 22:10; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026-05-20 22:00; UTC

Uždarbis

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026-05-20 21:38; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026-05-20 21:27; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026-05-20 21:20; UTC

Uždarbis

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026-05-20 21:19; UTC

Uždarbis

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026-05-20 21:18; UTC

Uždarbis

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026-05-20 21:17; UTC

Uždarbis

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026-05-20 21:16; UTC

Uždarbis

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Nanobiotix Prognozė

Kainos tikslas

By TipRanks

55.93% į viršų

12 mėnesių prognozė

Vidutinis 60 EUR 55.93%

Aukščiausias 60 EUR

Žemiausias 60 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Nanobiotix kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Nanobiotix akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

2.975 / 3.015Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.